- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 271/06 - 1,2,4-OxadiazolesHydrogenated 1,2,4-oxadiazoles
Patent holdings for IPC class C07D 271/06
Total number of patents in this class: 969
10-year publication summary
|
37
|
85
|
102
|
90
|
88
|
67
|
55
|
59
|
56
|
31
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| BASF SE | 21098 |
62 |
| Syngenta Participations AG | 1730 |
36 |
| Bristol-myers Squibb Company | 4826 |
26 |
| Receptos LLC | 62 |
26 |
| PTC Therapeutics, Inc. | 484 |
25 |
| Aurigene Oncology Limited | 119 |
19 |
| King Faisal University | 921 |
17 |
| PI Industries Ltd | 172 |
16 |
| Syngenta Crop Protection AG | 6259 |
15 |
| The Scripps Research Institute | 1355 |
15 |
| Cytokinetics, Inc. | 280 |
13 |
| Abbvie Inc. | 1817 |
12 |
| Merck Sharp & Dohme LLC | 3732 |
12 |
| Theravance Biopharma R&D IP, LLC | 453 |
11 |
| Sumitomo Chemical Company, Limited | 9109 |
10 |
| Bayer Cropscience AG | 1983 |
9 |
| Astellas Pharma Inc. | 1057 |
9 |
| Aurigene Discovery Technologies Limited | 99 |
9 |
| Modernatx, Inc. | 1288 |
9 |
| Shionogi & Co., Ltd. | 836 |
9 |
| Other owners | 609 |